Oral contraceptive pill for primary dysmenorrhoea

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2009, Pages

  Wong, Chooi L ^a   Farquhar, Cindy ^b   Roberts, Helen ^a   Proctor, Michelle ^c  

^a THE UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c Psychological Service   (New Zealand)

Author keywords

Contraceptives, oral, combined adverse effects; *therapeutic use ; Dysmenorrhea *drug therapy ; Female; Humans; Randomized controlled trials as topic

Indexed keywords

DANAZOL; MEFENAMIC ACID; NAPROXEN; ORAL CONTRACEPTIVE AGENT; PLACEBO;

CLINICAL TRIAL; DISEASE SEVERITY; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; HUMAN; MENORRHAGIA; MENSTRUATION; OUTCOME ASSESSMENT; PATIENT SATISFACTION; REVIEW; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT; DYSMENORRHEA; FEMALE; META ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC);

CONTRACEPTIVES, ORAL, COMBINED; DYSMENORRHEA; FEMALE; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67549092152     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD002120.pub3     Document Type: Review

References (41)

1. Bassol 2000 {published data only} Bassol S, Alvarado A, Celis C, Cravioto MC, Peralta O, Montano R, et al.Latin American experience with two low-dose oral contraceptives containing 30μg ethinylestradiol/75μg gestodene and 20μg ethinyl estradiol/150μg desogestrel. Contraception 2000; 62(3):131-5.
2. Buttram 1969a {published data only} Buttram VC, Kaufman RH. Primary dysmenorrhoea: combination vs sequential therapy. Texas Medicine 1969;65(8):52-5.
3. Buttram 1969b {published data only} Buttram VC, Kaufman RH. Primary dysmenorrhoea: combination vs sequential therapy. Texas Medicine 1969;65(8):52-5.
4. Cullberg 1972 {published data only} Cullberg J. Mood changes and menstrual symptoms with different gestagen/estrogen combinations. Acta Psychiatrica Scandinavia Supplementum 1972;236:1-86.
5. Davis 2005 {published and unpublished data} Davis AR, Osborne LM, O'Connell KJ, Westhoff CL. Challenges of conducting a placebo-controlled trial for dysmenorrhea in adolescents. Journal of Adolescent Health 2006;39:607-9. [DOI: 10.101.16/j.jadohealth.2006. 03.019]
6. * Davis AR, Westhoff C, O'Connell K, Callagher N. Oral contraceptives for dysmenorrhea in adolescent girls: A randomized trial. Obstetrics & Gynecology 2005;106(1):97-104.
7. O'Connell K, David AR, Kerns J. Oral contraceptives: side effects and depression in adolescent girls. Contraception 2007;75: 299-304. [: 10.1016/j.contraception.2006.09.008]
8. Endrikat 1999 {published data only} Endrikat J, Dusterberg B, Ruebig A, Gerlinger C, Strowitzki T. Comparison of efficacy, cycle control, and tolerability of two lowdose oral contraceptives in a multicenter clinical study. Contraception 1999;60(5):269-74.
9. GPRG 1968 {published data only} General Practitioner Research Group. Dysmenorrhoea unrelieved by an oral contraceptive. Practitioner 1968;200:856-9.
10. Hendrix 2002 {published data only} Hendrix SL, Alexander NJ. Primary dysmenorrhea treatment with a desogestrel-containing low-dose oral contraceptive. Contraception 2002;66(6):393-9.
11. Nakano 1971 {published data only} Nakano R, Takemura H. Treatment of function dysmenorrhoea: a double-blind study. Acta Obstetrica et Gynaecologica Japonica 1971; 18(1):41-4.
12. Serfaty 1998 {published data only} Serfaty D, Vree ML. A comparison of the cycle control and tolerability of two ultra low-dose oral contraceptives containing 20μg ethinyl estradiol and either 150μg desogestrel and 75μg gestodene. The European Journal of Contraception and Reproductive Health Care 1998;3(4):179-89.
13. Winkler 2003 {published and unpublished data} Winkler UH, Ferguson H, Mulders JAPA. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20μg ethinylestradiol. Contraception 2004;69(6):469-76.
14. Creatsas 1998 {published data only} Creatsas G, Cardamakis E, Deligeoroglou E, Hassan E, Tzingounis V. Tenoxicam versus lynestrenol-ethinyl estradiol treatment of dysfunctional uterine bleeding cases during adolescence. Journal of Paediatric & Adolescent Gynaecology 1998;11(4):177-180.
15. Foidart 2000 {published data only} Foidart JM, Wuttke W, Bouw GM, Gerlinger C, Heithecker R. A comparative investigation of contraceptive reliability, cycle control and tolerance of two monophasic oral contraceptives containing either drospirenone or desogestrel. The European Journal of Contraception and Reproductive Health Care 2000;5(2):124-34.
16. Iannotti 1991 {published data only} Iannotti G, DeFalco F, Paladini D, Ferraro F, Ragone R, Facchiano C, Ferrara A. Estrogen-progestagen and prostaglandin inhibitors in the treatment of primary dysmenorrhoea [Estroprogestinici ed antiprostaglandinici nelle terapia della dismenorrea primaria]. Giornale Italiano di Ostetricia e Ginecologia 1991;13(2):87-90.
17. Karasawa 1968 {published data only} Karasawa Y. Treatment of dysmenorrhoea with a mixed preparation of norethindrone and mestranol (S-3800C). Sanfujinka No Jissai - Practice of Gynecology & Obstetrics 1968;17(10):913-8.
18. Kaunitz 2000 {published data only} Kaunitz AM. Efficacy, cycle control, and safety of two triphasic oral contraceptives: Cyclessa (Desogestrel/Ethinyl Estradiol) and Ortho-Novum 7/7/7(Norethindrone/Ethinyl Estradiol): A randomised clinical trial. Contraception 2000;61(5):295-302.
19. Kremser 1971 {published data only} Kremser E, Mitchell GM. Treatment of primary dysmenorrhoea with a combined type oral contraceptive - a double blind study. Journal of the American College Health Association 1971;19(3): 195-6.
20. Kristjansdottir 2000 {published data only} Kristjansdottir J, Johansson EDB, Ruusuvaara L. The cost of the menstrual cycle in young Swedish women. The European Journal of Contraception and Reproductive Health Care 2000;5(2):152-6.
21. Kwiecien 2003 {published data only} Kwiecien M, Edelman A, Nichols MD, Jensen JT. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomised trial. Contraception 2003;67(1):9-13.
22. La Guardia 2003 {published data only} LaGuardia KD, Shangold G, Fisher A, Friedman A, Kafrissen M, the Norgestimate Study Group. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradio. Contraception 2003;67(6):431-437. 2003;67(6): 431-7.
23. Matthews 1968 {published data only} Matthews AE, Clarke JE. Double-blind trial of a sequential oral contraceptive (Sequens) in the treatment of dysmenorrhoea.. Journal of Obstetrics & Gynaecology of the British Commonwealth 1968;75(11):1117-22.
24. Moore 1999 {published data only} Moore C, Feichtinger W, Klinger G, Melliger U, Spona J, Walter F, Winkler UH, Zahradnik HP. Clinical findings with the dienogestcontaining oral contraceptive Valette(TM). Drugs of Today 1999;35 (Suppl. C):53-68.
25. Reisman 1999 {published data only} Reisman H, Deborah M, Gast MJ. A multicenter randomized comparison of cycle control and laboratory findings with oral contraceptive agents containing 100μg levonorgestrel with 20μg ethinyl estradiol or triphasic norethindrone with ethinyl estradiol. American Journal of Obstetrics & Gynecology 1999;181(5 part 2): S45-S52.
26. Tallian 1994 {published data only} Tallian F. Therapeutic possibilities using newer types of combined pills [Terapias lehetosegek ujabb tipusu kombinalt hormontablettakkal]. Magyar Noorvosok Lapja 1994;57:189-92.
27. Brill 1991 Brill K, Norpoth T, Schnitker J, Albring M. Clinical experience with a modern low-dose oral contraceptive in almost 100,000 users. Contraception 1991;43(2):101-110.
28. Chan 1981 Chan WY, Dawood MY, Fuchs F. Prostaglandins in primary dysmenorrhea: Comparison of prophylactic and non prophylactic treatment with ibuprofen and use of oral contraceptives. American Journal of Medicine 1981;70:535-41.
29. Coco 1999 Coco AS. Primary Dysmenorrhoea. American Family Physician 1999;60(2):489-96.
30. Dawood 1984 Dawood MY. Ibuprofen and dysmenorrhea. American Journal of Medicine 1984;77(1A):87-94.
31. Dawood 1990 Dawood MY. Dysmenorrhea. Clinical Obstetrics and Gynecology 1990;33(1):168-78.
32. Dawood 2006 Dawood MY. Primary Dysmenorrhea - Advances in pathogenesis and management. Obstetrics Gynaecology 2006;108:428- 41.
33. Gauthier 1992 Gauthier A, Upmalis D, Dain M. Clinical evaluation of a new triphasic oral contraceptive: norgestimate and ethinyl estradiol. Acta Obstetricia et Gynecologica Scandinavica Supplement 1992;71 (Suppl 156):27-32.
34. Goldzieher 1971 Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertility and Sterility 1971; 22(9):609-23.
35. Goldzieher 1995 Goldzieher JW, Zamah NM. Oral contraceptive side effects: Where's the beef?. Contraception 1995;52:327-35.
36. Karnaky 1975 Karnaky KJ. Development of the oral contraceptives. American Journal of Obstetrics and Gynecology 1975;123(7):771-772.
37. Melzack 1994 Melzack R, Katz J. Pain measurement in persons in pain. In: PD Wall, R Melzack editor(s). Textbook of Pain. 3rd Edition. London: Churchill Livingstone, 1994:337-351.
38. Milsom 1984 Milsom I, Andersch B. Effect of various oral contraceptive combinations on dysmenorrhea. Gynaecologic and Obstetric Investigation 1984;17:284-292.
39. Milsom 1990 Milsom I, Sundell G, Andersch B. The influence of different combined oral contraceptives on the prevalence and severity of dysmenorrhea. Contraception 1990;42(5):497-506.
40. Smith 1993 Smith RP. Cyclic pain and dysmenorrhea. Obstetrics and Gynecology Clinics of North America 1993;20(4):752-764.
41. Proctor 2001 Proctor ML, Roberts H, Farquhar CM. Combined oral contraceptive pill (OCP) as treatment for primary dysmenorrhoea. Cochrane Database of Systematic Reviews 2001, Issue 2. [DOI: 10.1002/14651858]